In LG1179 (Kras G13R; Kras mutants are typically non-responsive to EGFR TKIs), one 1.5 mg/kg dose of RN765C resulted in sustained tumor regression while multiple doses of carboplatin were ineffective and gemcitabine only moderately slowed down tumor growth (Figure 5B). This evidence concerns the gene KRAS and neoplasm.